AR089201A1 - Sistema de suministro transdermico - Google Patents
Sistema de suministro transdermicoInfo
- Publication number
- AR089201A1 AR089201A1 ARP120104673A ARP120104673A AR089201A1 AR 089201 A1 AR089201 A1 AR 089201A1 AR P120104673 A ARP120104673 A AR P120104673A AR P120104673 A ARP120104673 A AR P120104673A AR 089201 A1 AR089201 A1 AR 089201A1
- Authority
- AR
- Argentina
- Prior art keywords
- buprenorphine
- adhesive layer
- acid
- pressure
- sensitive adhesive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
Un sistema terapéutico transdérmico para la administración transdérmica de buprenorfina, que comprende una estructura de capa autoadhesiva que contiene buprenorfina que comprende A) una capa de refuerzo impermeable de buprenorfina, y B) una capa adhesiva sensible a la presión que contiene buprenorfina en dicha capa de refuerzo impermeable de buprenorfina, donde la capa adhesiva comprende a) al menos un adhesivo sensible a la presión en base a polímero, b) una cantidad analgésicamente efectiva de buprenorfina base o una sal farmacéuticamente aceptable de la misma, y c) un ácido carboxílico seleccionado del grupo que consiste en ácido oleico, ácido linoleico y ácido linolénico, ácido levulínico y mezclas de los mismos, en una cantidad suficiente de manera que dicha cantidad analgésicamente efectiva de buprenorfina sea solubilizada en éste para formar una mezcla y la mezcla de buprenorfina en ácido carboxílico forme depósitos dispersos en dicho adhesivo sensible a la presión, donde dicha capa adhesiva sensible a la presión que contiene buprenorfina es la capa en contacto con la piel y métodos de elaboración del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161569609P | 2011-12-12 | 2011-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089201A1 true AR089201A1 (es) | 2014-08-06 |
Family
ID=47754872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104673A AR089201A1 (es) | 2011-12-12 | 2012-12-12 | Sistema de suministro transdermico |
Country Status (27)
Country | Link |
---|---|
US (4) | US20140363487A1 (es) |
EP (1) | EP2790685B1 (es) |
JP (2) | JP6289378B2 (es) |
KR (1) | KR102014565B1 (es) |
CN (2) | CN107669662A (es) |
AP (1) | AP4036A (es) |
AR (1) | AR089201A1 (es) |
AU (1) | AU2012327247B2 (es) |
BR (1) | BR112014014137A2 (es) |
CA (1) | CA2858531C (es) |
CL (1) | CL2014001559A1 (es) |
CO (1) | CO7000779A2 (es) |
CR (1) | CR20140321A (es) |
DE (1) | DE112012005185T5 (es) |
EA (1) | EA201491164A1 (es) |
ES (1) | ES2647516T3 (es) |
GB (1) | GB2512007B8 (es) |
HK (2) | HK1201760A1 (es) |
IL (1) | IL233025A0 (es) |
MX (1) | MX352795B (es) |
PE (1) | PE20142341A1 (es) |
PH (1) | PH12014501231A1 (es) |
PL (1) | PL2790685T3 (es) |
SG (2) | SG11201403162XA (es) |
TN (1) | TN2014000233A1 (es) |
TW (1) | TW201338813A (es) |
WO (1) | WO2013088254A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
MX337286B (es) | 2007-05-25 | 2016-02-22 | Indivior Uk Ltd | Formulaciones de transferencia sostenida de compuestos de risperidona. |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2013086217A1 (en) | 2011-12-06 | 2013-06-13 | Masco Corporation Of Indiana | Ozone distribution in a faucet |
MX352795B (es) | 2011-12-12 | 2017-12-07 | Lts Lohmann Therapie Systeme Ag | Sistema de administracion transdermica que comprende buprenorfina. |
WO2013126552A1 (en) * | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EA201592246A1 (ru) | 2013-06-04 | 2016-05-31 | Лтс Лохманн Терапи-Системе Аг | Трансдермальная система доставки |
EP3016641B1 (de) | 2013-07-03 | 2018-09-05 | LTS Lohmann Therapie-Systeme AG | Transdermales therapeutisches system mit elektronischem bauteil |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
WO2015177209A1 (en) | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
EP3145504B1 (en) * | 2014-05-20 | 2023-07-26 | LTS Lohmann Therapie-Systeme AG | Transdermal delivery system including an interface mediator |
JP6573913B2 (ja) | 2014-05-20 | 2019-09-11 | エルテーエス ローマン テラピー−ジステーメ アーゲー | ロチゴチンを含む経皮送達システム |
MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
JP6660399B2 (ja) | 2015-03-10 | 2020-03-11 | ローズ テクノロジーズ | ブプレノルフィンの酢酸塩及びブプレノルフィンの調製方法 |
JP2018511127A (ja) | 2015-03-12 | 2018-04-19 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 渇望入力及び支援システム |
EP3067050A1 (en) | 2015-03-13 | 2016-09-14 | Acino AG | Transdermal therapeutic system with an overtape comprising two adhesive layers |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017048595A1 (en) * | 2015-09-14 | 2017-03-23 | Amneal Pharmaceuticals Llc | Transdermal delivery system |
US11458214B2 (en) | 2015-12-21 | 2022-10-04 | Delta Faucet Company | Fluid delivery system including a disinfectant device |
WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
JP2020503950A (ja) | 2017-01-06 | 2020-02-06 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 経皮薬剤送達の装置及び方法 |
WO2019064026A1 (en) | 2017-09-29 | 2019-04-04 | Orexo Ab | NEW PHARMACEUTICAL COMPOSITIONS |
GB201716830D0 (en) | 2017-10-13 | 2017-11-29 | Cambrex Charles City Inc | New Process |
US20210000756A1 (en) | 2018-03-13 | 2021-01-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer |
JP2021517572A (ja) | 2018-03-13 | 2021-07-26 | エルテーエス ローマン テラピー−ジステーメ アーゲー | シリコーンアクリルハイブリッドポリマーを含む経皮治療システム |
US20210008000A1 (en) | 2018-03-13 | 2021-01-14 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system comprising a silicone acrylic hybrid polymer |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
CN113952319A (zh) * | 2021-11-30 | 2022-01-21 | 烟台大学 | 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法 |
CN114397411A (zh) * | 2021-12-14 | 2022-04-26 | 苏州高迈药业有限公司 | 一种评价利丙双卡因乳膏的方法 |
WO2024040897A1 (zh) * | 2022-08-24 | 2024-02-29 | 新领医药技术(深圳)有限公司 | 沙利度胺或其类似物透皮贴剂及其制备方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US119585A (en) * | 1871-10-03 | Improvement in horse-collars and hames | ||
GB1136214A (en) | 1965-06-15 | 1968-12-11 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US3474101A (en) | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
CA2002299A1 (en) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
DE3939376C1 (es) * | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
US5635203A (en) * | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19922662C1 (de) | 1999-05-18 | 2000-12-28 | Sanol Arznei Schwarz Gmbh | Transdermales therapeutisches System (TTS) Tolterodin enthaltend |
DE19958554C2 (de) | 1999-07-02 | 2002-06-13 | Lohmann Therapie Syst Lts | Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung |
CZ301726B6 (cs) | 1999-07-02 | 2010-06-02 | Lts Lohmann Therapie-Systeme Ag | Mikrorezervoárový systém na bázi polysiloxanu a ambifilních rozpouštedel |
WO2001014336A1 (fr) * | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Derives benzeniques substitues par un cycle aromatique, et leur procede de production |
JP2003522144A (ja) | 2000-02-08 | 2003-07-22 | ユーロ−セルティーク,エス.エイ. | オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物 |
JP4659943B2 (ja) * | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | 塩酸ブプレノルフィン含有貼付剤 |
US6844727B2 (en) * | 2000-06-28 | 2005-01-18 | Baker Hughes Incorporated | Method and apparatus of reducing ringing in a nuclear magnetic resonance probe |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
JP2004525960A (ja) * | 2001-02-16 | 2004-08-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 尿失禁、特に切迫尿失禁の治療用経皮デリバリーディバイスの製造にブプレノルフィンを使用する方法 |
DE10141651B4 (de) | 2001-08-24 | 2007-02-15 | Lts Lohmann Therapie-Systeme Ag | Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung |
DE10213772A1 (de) | 2002-03-27 | 2003-10-09 | Gruenenthal Gmbh | Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen |
US20050118245A1 (en) | 2002-03-27 | 2005-06-02 | Wilsmann Klaus M. | Assembled unit consisting of individually separable, transdermal, therapeutic systems |
US20050191340A1 (en) * | 2002-08-09 | 2005-09-01 | Gruenenthal Gmbh | Opioid-receptor antagonists in transdermal systems having buprenorphine |
DE50307717D1 (de) * | 2002-08-09 | 2007-08-30 | Gruenenthal Gmbh | Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin |
JP5054893B2 (ja) | 2002-12-13 | 2012-10-24 | ユーロ−セルティーク エス.エイ. | 鎮痛のためのブプレノルフィン経皮投与計画 |
RU2324372C2 (ru) | 2003-03-25 | 2008-05-20 | Моринда, Инк. | Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека |
US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US7182955B2 (en) * | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
DE102004045599A1 (de) | 2004-09-17 | 2006-03-23 | Grünenthal GmbH | System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen |
DE102004062647A1 (de) | 2004-12-21 | 2006-06-29 | Kronotec Ag | Holzfaserdämmstoffplatte bzw.- matte |
DE102004062614B4 (de) | 2004-12-24 | 2011-12-29 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung |
DE102006054732B4 (de) | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren |
DE102006054731B4 (de) * | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
EP2366388A1 (de) | 2010-03-17 | 2011-09-21 | Ratiopharm GmbH | Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin |
MX352795B (es) * | 2011-12-12 | 2017-12-07 | Lts Lohmann Therapie Systeme Ag | Sistema de administracion transdermica que comprende buprenorfina. |
AU2013205080B2 (en) | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
EA201592246A1 (ru) | 2013-06-04 | 2016-05-31 | Лтс Лохманн Терапи-Системе Аг | Трансдермальная система доставки |
-
2012
- 2012-12-12 MX MX2014007020A patent/MX352795B/es active IP Right Grant
- 2012-12-12 JP JP2014546672A patent/JP6289378B2/ja active Active
- 2012-12-12 SG SG11201403162XA patent/SG11201403162XA/en unknown
- 2012-12-12 AR ARP120104673A patent/AR089201A1/es unknown
- 2012-12-12 PE PE2014000948A patent/PE20142341A1/es not_active Application Discontinuation
- 2012-12-12 AP AP2014007779A patent/AP4036A/en active
- 2012-12-12 WO PCT/IB2012/002973 patent/WO2013088254A1/en active Application Filing
- 2012-12-12 SG SG10201604754VA patent/SG10201604754VA/en unknown
- 2012-12-12 TW TW101146918A patent/TW201338813A/zh unknown
- 2012-12-12 EA EA201491164A patent/EA201491164A1/ru unknown
- 2012-12-12 PL PL12826670T patent/PL2790685T3/pl unknown
- 2012-12-12 KR KR1020147019186A patent/KR102014565B1/ko active IP Right Grant
- 2012-12-12 BR BR112014014137A patent/BR112014014137A2/pt not_active Application Discontinuation
- 2012-12-12 EP EP12826670.7A patent/EP2790685B1/en active Active
- 2012-12-12 ES ES12826670.7T patent/ES2647516T3/es active Active
- 2012-12-12 CA CA2858531A patent/CA2858531C/en active Active
- 2012-12-12 US US14/364,192 patent/US20140363487A1/en not_active Abandoned
- 2012-12-12 CN CN201711075001.2A patent/CN107669662A/zh active Pending
- 2012-12-12 DE DE112012005185.8T patent/DE112012005185T5/de active Pending
- 2012-12-12 CN CN201280069476.XA patent/CN104114161A/zh active Pending
- 2012-12-12 AU AU2012327247A patent/AU2012327247B2/en active Active
- 2012-12-12 GB GB1412385.5A patent/GB2512007B8/en active Active
-
2014
- 2014-05-28 TN TNP2014000233A patent/TN2014000233A1/en unknown
- 2014-05-30 PH PH12014501231A patent/PH12014501231A1/en unknown
- 2014-06-08 IL IL233025A patent/IL233025A0/en unknown
- 2014-06-12 CL CL2014001559A patent/CL2014001559A1/es unknown
- 2014-07-04 CR CR20140321A patent/CR20140321A/es unknown
- 2014-07-11 CO CO14149730A patent/CO7000779A2/es unknown
-
2015
- 2015-03-12 HK HK15102525.3A patent/HK1201760A1/xx unknown
- 2015-04-13 HK HK15103564.3A patent/HK1203048A1/xx unknown
-
2016
- 2016-01-11 US US14/992,122 patent/US9549903B2/en active Active
- 2016-10-07 JP JP2016198650A patent/JP2017036304A/ja active Pending
- 2016-10-10 US US15/289,507 patent/US20170049713A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,920 patent/US20200306204A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089201A1 (es) | Sistema de suministro transdermico | |
PE20151147A1 (es) | Sistema de liberacion transdermica | |
NI201500170A (es) | Sistema de liberación transdermico | |
ES2581574T3 (es) | Sistema terapéutico transdérmico para la administración del principio activo buprenorfina | |
AR058598A1 (es) | Administracion transdermica de meptazinol | |
RU2018102104A (ru) | Способ обеспечения полезного воздействия на кожу | |
AR086966A1 (es) | Metodo para la inhibicion o control de la liberacion de agente para tratamiento de pozos | |
DOP2006000168A (es) | Dispositivos transdérmicos de liberación de fármaco que contienen drospirenona y métodos de liberación de los mismos | |
CL2008001605A1 (es) | Una formulacion de dosis intranasal que comprende asenapina o una sal farmaceuticamente aceptable y un portador liquido que contiene agua y un poliol, util para el tratamiento de la esquizofrenia. | |
MX2014002215A (es) | Sistema terapeutico transdermico para clorhidrato de acido 5-aminolevulinico. | |
EA201300648A1 (ru) | Трансдермальная терапевтическая система (tts), содержащая ротиготин | |
MX2015010967A (es) | Formulaciones transdermicas de laquinimod. | |
ECSP14008829A (es) | Sistema de administracion transdermica | |
RU2012146166A (ru) | Способ профилактики поражения слизистой оболочки желудка при иммобилизации в эксперименте | |
AR105534A1 (es) | Sistema de suministro transdérmico | |
RU2012145292A (ru) | Способ профилактики поражения слизистой оболочки желудка при иммобилизации в эксперименте |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |